Compare Recursion Pharmaceuticals Inc (RXRX) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Royal Bank of Canada — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Royal Bank of Canada trades at $210.37 (market cap $289.51B). The key difference: Royal Bank of Canada is far larger — about 189.2× Recursion Pharmaceuticals Inc's market cap, and Royal Bank of Canada pays a 2.42% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | RY | |
|---|---|---|
Market Cap | $1.53B | $289.51B |
Sector | Health | Financials |
52-Week High | $6.79 | $217.87 |
52-Week Low | $2.84 | $128.46 |
Enterprise Value | $946.50M | — |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Royal Bank of Canada (RY) trades at $210.37, down 2.35% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. Recent financial performance includes robust revenue growth to $66.53B in 2025 and a healthy net income margin of 31.85%, while the company maintains a solid dividend program with recent increases.
RY presents a mixed outlook with strong fundamentals and analyst support but faces valuation concerns. The company's consistent earnings beats and shareholder returns through dividends and buybacks provide upside potential, though elevated P/E and P/S ratios warrant caution. Key risks include economic sensitivity and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
